4//SEC Filing
SPHERA FUNDS MANAGEMENT LTD. 4
Accession 0001178913-21-001591
CIK 0001785530other
Filed
May 3, 8:00 PM ET
Accepted
May 4, 1:21 PM ET
Size
15.3 KB
Accession
0001178913-21-001591
Insider Transaction Report
Form 4
SPHERA FUNDS MANAGEMENT LTD.
10% Owner
Transactions
- Purchase
Common Stock
2021-05-04$16.00/sh+475,000$7,600,000→ 787,997 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-05-04−2,713,410→ 0 total(indirect: See footnote)→ Common Stock (312,997 underlying) - Conversion
Common Stock
2021-05-04+312,997→ 312,997 total(indirect: See footnote)
Sphera Global Healthcare GP Ltd.
10% Owner
Transactions
- Conversion
Common Stock
2021-05-04+312,997→ 312,997 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-05-04−2,713,410→ 0 total(indirect: See footnote)→ Common Stock (312,997 underlying) - Purchase
Common Stock
2021-05-04$16.00/sh+475,000$7,600,000→ 787,997 total(indirect: See footnote)
Transactions
- Purchase
Common Stock
2021-05-04$16.00/sh+475,000$7,600,000→ 787,997 total(indirect: See footnote) - Conversion
Common Stock
2021-05-04+312,997→ 312,997 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-05-04−2,713,410→ 0 total(indirect: See footnote)→ Common Stock (312,997 underlying)
Footnotes (5)
- [F1]Includes (a) 187,798 shares held by Sphera Global Healthcare Master Fund (the "Healthcare Fund") and (b) 125,199 shares held by Sphera Biotech Master Fund, LP (the "Biotech Fund" and, together with the Healthcare Fund, the "Funds").
- [F2]On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F3]Sphera Global Healthcare Management LP is the investment manager for the Funds (the "Management Company"). The Management Company is managed, controlled and operated by its general partner Sphera Global Healthcare GP Ltd. (the "General Partner"), of which Sphera Funds Management Ltd. ("SFML") is the controlling shareholder. Each of the Management Company, the General Partner and SFML may be deemed the indirect beneficial owner of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended.
- [F4]Includes (a) 300,000 shares held by the Healthcare Fund and (b) 175,000 shares held by the Biotech Fund.
- [F5]Includes (a) 487,798 shares held by the Healthcare Fund and (b) 300,199 shares held by Biotech Fund.
Documents
Issuer
Werewolf Therapeutics, Inc.
CIK 0001785530
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001496201
Filing Metadata
- Form type
- 4
- Filed
- May 3, 8:00 PM ET
- Accepted
- May 4, 1:21 PM ET
- Size
- 15.3 KB